FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035893738> ?p ?o ?g. }

• W2035893738 endingPage "1825" @default.
• W2035893738 startingPage "1819" @default.
• W2035893738 abstract "Purpose Modest toxicity and possibly enhanced activity makes continuous-infusion fluorouracil (FU) an attractive alternative to FU plus leucovorin (FU/LV) for the adjuvant treatment of colorectal cancer. Intergroup trial 0153 (Southwest Oncology Group trial 9415) was developed to compare the efficacy of continuous-infusion FU (CIFU) plus levamisole to FU/LV plus levamisole in the adjuvant treatment of high-risk Dukes' B2 and C1 or C2 colon cancer. Patients and Methods After surgery, patients were randomly assigned to CIFU 250 mg/m 2 /d for 56 days every 9 weeks for three cycles or FU 425 mg/m 2 and LV 20 mg/m 2 daily for 5 days every 28 to 35 days for six cycles. All patients received levamisole 50 mg tid for 3 days every other week. The primary end point was overall survival (OS). Results The study closed in December 1999 after an interim analysis demonstrated little likelihood of CIFU showing superiority to FU/LV within the stipulated hazard ratio. A total of 1,135 patients were registered. At least one grade 4 toxicity occurred in 39% of patients receiving FU/LV and 5% of patients receiving CIFU. However, almost twice as many patients receiving CIFU discontinued therapy early compared with those receiving FU/LV. The 5-year OS is 70% (95% CI, 66% to 74%) for FU/LV and 69% (95% CI, 64% to 73%) for CIFU. The corresponding 5-year disease-free survival (DFS) is 61% (95% CI, 56% to 65%) and 63% (95% CI, 59% to 68%), respectively. For all patients, 5-year OS is 83%, 74%, and 55%; 5-year DFS is 78%, 67%, and 47% for N0, N1, and N2-3, respectively. Conclusion CIFU had less severe toxicity but did not improve DFS or OS in comparison with bolus FU/LV." @default.
• W2035893738 created "2016-06-24" @default.
• W2035893738 creator A5002909505 @default.
• W2035893738 creator A5004963523 @default.
• W2035893738 creator A5006604886 @default.
• W2035893738 creator A5038888315 @default.
• W2035893738 creator A5050307933 @default.
• W2035893738 creator A5055389521 @default.
• W2035893738 creator A5063294358 @default.
• W2035893738 creator A5077337021 @default.
• W2035893738 creator A5080788977 @default.
• W2035893738 date "2005-03-20" @default.
• W2035893738 modified "2023-10-18" @default.
• W2035893738 title "Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer" @default.
• W2035893738 cites W1795564265 @default.
• W2035893738 cites W1811602282 @default.
• W2035893738 cites W1840481440 @default.
• W2035893738 cites W1902766545 @default.
• W2035893738 cites W1910716144 @default.
• W2035893738 cites W1962875322 @default.
• W2035893738 cites W1982857502 @default.
• W2035893738 cites W1997845311 @default.
• W2035893738 cites W2016791396 @default.
• W2035893738 cites W2034246374 @default.
• W2035893738 cites W2058680827 @default.
• W2035893738 cites W2108509187 @default.
• W2035893738 cites W2137408681 @default.
• W2035893738 cites W2139393303 @default.
• W2035893738 cites W2140626944 @default.
• W2035893738 cites W2159848047 @default.
• W2035893738 cites W2161174144 @default.
• W2035893738 cites W2163564081 @default.
• W2035893738 cites W2165070253 @default.
• W2035893738 cites W2169275199 @default.
• W2035893738 cites W2225065195 @default.
• W2035893738 cites W2227311140 @default.
• W2035893738 cites W2230119135 @default.
• W2035893738 cites W2248563460 @default.
• W2035893738 cites W2255487108 @default.
• W2035893738 cites W2313857605 @default.
• W2035893738 cites W2323577539 @default.
• W2035893738 cites W2396646859 @default.
• W2035893738 cites W2469345929 @default.
• W2035893738 cites W4239883393 @default.
• W2035893738 cites W598519044 @default.
• W2035893738 doi "https://doi.org/10.1200/jco.2005.04.169" @default.
• W2035893738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15774775" @default.
• W2035893738 hasPublicationYear "2005" @default.
• W2035893738 type Work @default.
• W2035893738 sameAs 2035893738 @default.
• W2035893738 citedByCount "109" @default.
• W2035893738 countsByYear W20358937382012 @default.
• W2035893738 countsByYear W20358937382013 @default.
• W2035893738 countsByYear W20358937382014 @default.
• W2035893738 countsByYear W20358937382015 @default.
• W2035893738 countsByYear W20358937382016 @default.
• W2035893738 countsByYear W20358937382017 @default.
• W2035893738 countsByYear W20358937382019 @default.
• W2035893738 countsByYear W20358937382020 @default.
• W2035893738 countsByYear W20358937382022 @default.
• W2035893738 crossrefType "journal-article" @default.
• W2035893738 hasAuthorship W2035893738A5002909505 @default.
• W2035893738 hasAuthorship W2035893738A5004963523 @default.
• W2035893738 hasAuthorship W2035893738A5006604886 @default.
• W2035893738 hasAuthorship W2035893738A5038888315 @default.
• W2035893738 hasAuthorship W2035893738A5050307933 @default.
• W2035893738 hasAuthorship W2035893738A5055389521 @default.
• W2035893738 hasAuthorship W2035893738A5063294358 @default.
• W2035893738 hasAuthorship W2035893738A5077337021 @default.
• W2035893738 hasAuthorship W2035893738A5080788977 @default.
• W2035893738 hasConcept C121608353 @default.
• W2035893738 hasConcept C126322002 @default.
• W2035893738 hasConcept C141071460 @default.
• W2035893738 hasConcept C146357865 @default.
• W2035893738 hasConcept C151730666 @default.
• W2035893738 hasConcept C168563851 @default.
• W2035893738 hasConcept C203092338 @default.
• W2035893738 hasConcept C207103383 @default.
• W2035893738 hasConcept C2776694085 @default.
• W2035893738 hasConcept C2777863537 @default.
• W2035893738 hasConcept C2780456651 @default.
• W2035893738 hasConcept C2781325985 @default.
• W2035893738 hasConcept C29730261 @default.
• W2035893738 hasConcept C44249647 @default.
• W2035893738 hasConcept C526805850 @default.
• W2035893738 hasConcept C61943457 @default.
• W2035893738 hasConcept C71924100 @default.
• W2035893738 hasConcept C86803240 @default.
• W2035893738 hasConcept C90924648 @default.
• W2035893738 hasConceptScore W2035893738C121608353 @default.
• W2035893738 hasConceptScore W2035893738C126322002 @default.
• W2035893738 hasConceptScore W2035893738C141071460 @default.
• W2035893738 hasConceptScore W2035893738C146357865 @default.
• W2035893738 hasConceptScore W2035893738C151730666 @default.
• W2035893738 hasConceptScore W2035893738C168563851 @default.
• W2035893738 hasConceptScore W2035893738C203092338 @default.
• W2035893738 hasConceptScore W2035893738C207103383 @default.
• W2035893738 hasConceptScore W2035893738C2776694085 @default.

• next